Home・Elenco Azioni・Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

280.45 0.11

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

278.27

Massimo

286.83

Metriche Chiave
By Trading Economics
Entrata	62M 49M
Vendite	12M 64M
P/E Media del settore	29.524 57.366
EPS	2.22
Margine di Profitto	76.159
Dipendenti	47
EBITDA	87M 72M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+25.23% upside

Dividendi
By Acuity
Utili prossimi	5 nov 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-267M 5.6B
Apertura precedente	280.34
Chiusura precedente	280.45

Notizie sul Sentiment di mercato

By Acuity

35%

65%

136 / 340 Classifica in Healthcare

Ligand Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

25 ago 2026, 19:46 UTC

Ligand Pharmaceuticals Inc is trading higher, benefiting from a favorable market environment amid declining crude oil prices and lower Treasury yields.

24 ago 2026, 19:56 UTC

Ligand Pharmaceuticals is trading lower during Monday's session, marking the fourth consecutive day of declines. No specific news has been identified to explain the drop.

21 ago 2026, 19:36 UTC

News

Ligand Pharmaceuticals is gaining today, supported by strong long-term performance and a market capitalization of $5.76 billion.

19 ago 2026, 19:11 UTC

Ligand Pharmaceuticals Inc is rising today, driven by strong momentum in the Pharmaceuticals sub-sector and unusually high market volume.

18 ago 2026, 19:16 UTC

Ligand Pharmaceuticals Inc is trading lower, continuing a downward trend amid rising U.S. Treasury yields and inflation concerns related to geopolitical tensions.

17 ago 2026, 20:06 UTC

Ligand Pharmaceuticals Inc is declining during Monday's session, amid broader economic concerns following a drop in U.S. retail sales for July.

14 ago 2026, 19:46 UTC

News

Ligand Pharmaceuticals Inc shares are higher after Leerink analyst David Risinger initiated coverage with an Outperform rating and a price target of $330.00.

13 ago 2026, 19:52 UTC

News

Ligand Pharmaceuticals Inc shares are lower amid high trading volume, as initial jobless claims rose and the Producer Price Index remained flat.

12 ago 2026, 19:16 UTC

Ligand Pharmaceuticals Inc shares are higher today, reflecting strength in U.S. stocks amid gains in AI-related companies and ongoing geopolitical tensions.

11 ago 2026, 19:16 UTC

Ligand Pharmaceuticals Inc shares are lower today, experiencing volatility amid rising oil prices and inflation concerns ahead of key U.S. inflation data.

10 ago 2026, 21:51 UTC

Ligand Pharmaceuticals Inc shares declined in after-market hours, continuing a downward trend with no specific news to explain the movement.

7 ago 2026, 20:02 UTC

News

Ligand Pharmaceuticals Inc shares are lower despite a strong second-quarter performance, as profit-taking and high trading volume weigh on the stock.

6 ago 2026, 20:03 UTC

News

Ligand Pharmaceuticals Inc reported strong Q2 results, with adjusted EPS of $2.37, exceeding expectations. The company raised its full-year EPS guidance amid sector gains.

5 ago 2026, 19:26 UTC

Ligand Pharmaceuticals Inc shares are higher during Wednesday's session, despite pulling back from earlier gains. Broader market sentiment is supported by declining crude oil prices.

3 ago 2026, 19:36 UTC

News

Oppenheimer raised its price target on Ligand Pharmaceuticals to $326, reinforcing positive investor sentiment as shares trade higher during Monday's session.

31 lug 2026, 23:36 UTC

Ligand Pharmaceuticals Inc shares are lower in after-market trading, influenced by broader market pressure from Apple's weaker guidance. No specific company news was identified.

30 lug 2026, 22:16 UTC

Ligand Pharmaceuticals Inc shares are higher in after-market hours, despite routine trading and no specific news driving the price action.

29 lug 2026, 21:02 UTC

Ligand Pharmaceuticals Inc. shares are higher in after-market hours, despite broader market volatility and a six-session decline leading up to today.

28 lug 2026, 19:22 UTC

Ligand Pharmaceuticals Inc is lower today, continuing a five-session decline, with no specific news driving the movement and unusually high trading volume.

27 lug 2026, 19:26 UTC

News

Ligand Pharmaceuticals Inc. shares are lower today, continuing a four-session decline amid concerns over its recent acquisition of XOMA Royalty Corp.

24 lug 2026, 22:06 UTC

Ligand Pharmaceuticals Inc. shares were little changed in after-market trading, with no specific news identified. Broader market trends showed mixed signals.

23 lug 2026, 21:03 UTC

Ligand Pharmaceuticals Inc shares are higher in after-market trading, following a rise in crude oil prices amid geopolitical tensions, though no specific company news was identified.

21 lug 2026, 20:02 UTC

News

Ligand Pharmaceuticals is higher after Citi resumed coverage with a Buy rating and a price target of $387, citing benefits from the XOMA acquisition.

Confronto tra pari

Modifica del prezzo

Ligand Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

25.23% in crescita

Previsioni per 12 mesi

Media 350.86 USD 25.23%

Alto 390 USD

Basso 326 USD

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Ligand Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

8 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 8 che hanno fornito valutazioni azionarie a Ligand Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

136 / 340 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.